Here's What Caused Arrowhead Pharmaceuticals' Stock to Spike Today
After Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced Thursday that it has crafted a new drug development platform, and created a handful of candidate compounds, shares of the clinical-stage biotech, which is focused on RNAi drug development, rose by 14.7% as of 12:05 p.m. EDT on Friday.
Arrowhead stated that it will be hosting a research and development meeting later Friday where it will provide investors with an overview of its new Targeted RNAi Molecule (TRiM) drug development platform, and sharing a few details about some of its product candidates.
Arrowhead's management team asserts that the TRiM platform will provide the company with several advantages, including:
Source: Fool.com
Arrowhead Pharmaceuticals Inc. Stock
€26.67
-0.110%
With 21 Buy predictions and 2 Sell predictions Arrowhead Pharmaceuticals Inc. is one of the favorites of our community.
Based on the current price of 26.67 € the target price of 54 € shows a potential of 102.47% for Arrowhead Pharmaceuticals Inc. which would more than double the current price.
